myota

Myota is a UK-based health-tech company founded in 2019 by computational biologist Dr. Thomas Gurry and startup veteran Katherine Stennett. The company's creation was inspired by Dr. Gurry's decade of research at institutions like MIT, where he discovered that individuals' microbiomes react very differently to the same dietary fibres. This insight led to the development of patented prebiotic fibre blends designed to be effective across a wide range of gut microbiome types.

The company's core business revolves around formulating and selling precision fibre supplements that aim to improve gut health, which is linked to preventing chronic conditions such as Type 2 Diabetes, IBS, and arthritis. Myota operates on a direct-to-consumer subscription model, offering various flavourless and flavoured powder blends that can be mixed into food and drinks. Its products, such as the 'Gut Booster', 'Metabolic Booster', and 'Immunity Booster', are developed in its Swiss lab and are clinically tested. The 'Gut Booster' is notably Low FODMAP certified, making it suitable for people with IBS and other digestive sensitivities.

Myota also offers a microbiome testing kit that provides users with a personalised analysis of their gut's fermentation profile, enabling the company's dietitians to offer tailored dietary guidance. The business model combines product sales with personalised health insights, tapping into the growing consumer focus on at-home health solutions. Myota has partnered with healthcare services, including the NHS, to conduct clinical trials and further research the impact of its fibre blends on various health conditions.

Keywords: gut health, prebiotic fibre, microbiome testing, direct-to-consumer, health-tech, supplements, digestive health, personalised nutrition, clinical trials, chronic disease prevention, low FODMAP, gut bacteria, short-chain fatty acids, SCFA, scientific research, e-commerce, wellness, nutrition, food supplements, health and wellness